癌症合并脓毒性休克患者的早期红细胞输血策略:TRANSPORT随机对照试验
TRANSPORT为法国18中心优效性RCT,纳入血液或实体恶性肿瘤合并脓毒性休克、乳酸>2.0 mmol/L且Hb<9.0 g/dL的成人患者,随机接受Hb阈值9.0 g/dL(宽松组93例)或7.0 g/dL(限制性组94例)指导的红细胞输注,观察期复苏最初48小时。主要终点12小时乳酸下降(≤2.0 mmol/L或较基线相对下降30%)在宽松组与限制性组分别为52%和50%(OR 1.07;95%CI 0.60–1.90;P=0.82)。宽松组动脉或静脉血栓事件更多(13% vs 1%;P=0.001),28天死亡率46% vs 53%(P=0.34)。试验因安全顾虑提前终止,原计划260例仅入组187例。
要点
- 癌症合并脓毒性休克且Hb<9.0 g/dL者,宽松输血(阈值9.0 g/dL)较限制性(7.0 g/dL)未提高12小时乳酸下降率(52% vs 50%;OR 1.07;95%CI 0.60–1.90;P=0.82)。
- 宽松组动脉或静脉血栓事件显著更多(13% vs 1%;P=0.001),提示需警惕血栓风险。
- 28天死亡率宽松组46%、限制性组53%(P=0.34),无统计学差异,原文不支持下述任何一方常规优先。
- 该试验因安全顾虑提前终止,原计划260例仅纳入187例,结果需谨慎解读。
适用人群与场景
- 法国18中心成人血液或实体恶性肿瘤合并脓毒性休克患者,乳酸>2.0 mmol/L且血红蛋白<9.0 g/dL,在复苏最初48小时内随机分组。
诊断标准与关键阈值
- 脓毒性休克合并恶性肿瘤,乳酸>2.0 mmol/L且血红蛋白<9.0 g/dL为纳入条件。
- 主要终点12小时乳酸下降定义为乳酸正常化≤2.0 mmol/L或较基线相对下降30%。
- 输血策略由血红蛋白阈值界定:宽松组9.0 g/dL,限制性组7.0 g/dL(复苏最初48小时)。
处置流程与药物剂量
- 第一步:对癌症合并脓毒性休克、乳酸>2.0 mmol/L且Hb<9.0 g/dL的成人患者评估是否符合试验条件。
- 第二步:按血红蛋白阈值决定红细胞输注——宽松组阈值9.0 g/dL,限制性组阈值7.0 g/dL,观察期为复苏最初48小时。
- 原文未提及具体输血剂量、单位、频次或目标血红蛋白维持值。
红旗征与不能漏的情况
- 宽松输血组动脉或静脉血栓事件发生率13%,显著高于限制性组1%(P=0.001),需警惕血栓事件。
- 试验因安全顾虑提前终止,提示该人群输血策略存在安全性不确定。
研究设计与关键结果
- 多中心优效性RCT,法国18中心,计划入组260例但因安全顾虑提前终止,实际纳入187例(宽松组93例、限制性组94例)。
- 主要终点12小时乳酸下降:宽松组52% vs 限制性组50%(OR 1.07;95%CI 0.60–1.90;P=0.82),未显示优效。
- 动脉或静脉血栓事件:宽松组13% vs 限制性组1%(P=0.001)。
- 28天死亡率:宽松组46% vs 限制性组53%(P=0.34)。
证据类型、等级与局限
- 证据类型:多中心(18中心)优效性随机对照试验。
- 局限:因安全顾虑提前终止,样本量187例低于计划260例,统计效能受限;原文未给出证据等级或推荐强度。
对床旁实践的改变
- 对癌症合并脓毒性休克、Hb<9.0 g/dL的患者,不因宽松输血(阈值9.0 g/dL)能改善乳酸清除而常规采用该策略。
- 宽松输血组血栓事件更多(13% vs 1%),选择输血阈值时需权衡血栓风险,尤其对血栓高风险患者。
- 原文结论不支持下述任一策略常规优先于另一策略;因试验提前终止,结果需结合个体情况谨慎解读。
指南或共识出处
- TRANSPORT随机对照试验,发表于Intensive Care Med,原文未提及具体年份。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Septic shock in cancer patients remains associated with a grim prognosis. With regard to the high prevalence of anemia, the optimal hemoglobin target to restore tissue oxygenation remains uncertain.
METHODS: This was a multicenter superiority randomized controlled trial carried out in 18 centers in France. Adult patients with hematological or solid malignancies presenting with septic shock with lactate level > 2.0 mmol/L and hemoglobin level < 9.0 g/dL were randomly assigned to liberal or restrictive red blood cell (RBC) transfusion directed by hemoglobin thresholds of 9.0 g/dL or 7.0 g/dL during the first 48 h of resuscitation. The primary endpoint was 12-h lactate reduction, defined as normalization ≤ 2.0 mmol/L or relative decrease by 30% from baseline. Key secondary endpoints included ICU-acquired infections, arterial and venous thrombotic events, and 28-day mortality.
RESULTS: The trial was designed to enroll 260 patients but was prematurely stopped for safety concerns. Finally, 187 patients were enrolled, distributed into 93 in the liberal arm and 94 in the restrictive arm. Twelve-hour lactate reduction was achieved in 52% and 50% of patients in the liberal and restrictive arms, respectively (odds ratio 1.07; 95% confidence interval 0.60 to 1.90; P = 0.82). Arterial or venous thrombotic events occurred more frequently in the liberal group (13% vs. 1%; P = 0.001), and 28-day mortality rates were 46% and 53% (P = 0.34), respectively.
CONCLUSIONS: In cancer patients with septic shock, this trial did not demonstrate superiority of liberal over restrictive transfusion strategy. The absence of mortality benefit and the uncertainty surrounding the observed imbalance in adverse events do not support the routine preference of either transfusion strategy over the other.
参考来源
- Pène F, Vigneron C, Lafarge A, et al. Early red blood cell transfusion strategy in septic shock among patients with cancer: the TRANSPORT randomized controlled trial. Intensive Care Med. 2026. PMID: 42616082. doi:10.1007/s00134-026-08582-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。